Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 4/17/15 → 4/17/21 |
Funding
- Merck Sharp & Dohme Corporation (Prot #MK3475-055)
Prot #MK3475-055: A Phase II Clinical Trial of Single Agent Pembrolizumab (MK-3475) in Subjects with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Who Have Failed Platinum and Cetuximab
- Agulnik, Mark (PD/PI)
Project: Research project